In journal’s inaugural articles, Micael Lopez-Acevedo, Angeles Secord and colleagues explore the activity of dasatinib in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines in order to determine if dasatinib inhibits the SRC pathway [10], a review article by Steven J Gibson and colleagues provides an overview of drug discovery in the ovarian cancer arena [11], and Cassandra D. Foss, et al. determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in order to predict therapeutic targets for chemotherapy [12]. This evidence concerns the gene SRC and ovarian carcinoma.